Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808585 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF
A Phase 2 study, sponsored by PhaseBio Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
NCT02808585 is a Phase 2 study that has completed, run by PhaseBio Pharmaceuticals. The registered enrollment target is 29 participants.
The verdict
NCT02808585, a Phase 2 study, has completed, sponsored by PhaseBio Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study will be a sequential multiple-dose escalation study that will enroll (randomize and dose) approximately 28 subjects in four cohorts consisting of 3 active and 1 placebo in Cohort 1 and 6 active and 2 placebo in subsequent cohorts. Randomized subjects will receive a fixed weekly dose of study drug or placebo for a 4 week dosing period.
Interventions
- DRUG Placebo Injection
- DRUG PB1046 Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-12-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02808585
The ClinicalTrials.gov registry entry for NCT02808585 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PhaseBio Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Injection is the first listed.
NCT02808585 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02808585 about?
NCT02808585 is a clinical study titled "Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF". This study will be a sequential multiple-dose escalation study that will enroll (randomize and dose) approximately 28 subjects in four cohorts consisting of 3 active and 1 placebo in Cohort 1 and 6 active and 2 placebo in subsequent cohorts. Randomized subjects will receive a fixed weekly dose of st...
What is the current status of trial NCT02808585?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2016-06. Estimated completion is 2017-12-06.
What interventions are being tested in trial NCT02808585?
The interventions under investigation include: Placebo Injection (DRUG), PB1046 Injection (DRUG).
Who is sponsoring clinical trial NCT02808585?
This trial is sponsored by PhaseBio Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.